<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384434</url>
  </required_header>
  <id_info>
    <org_study_id>RO 14-001</org_study_id>
    <nct_id>NCT02384434</nct_id>
  </id_info>
  <brief_title>Low Level Laser Therapy for Radiation Induced Dermatitis in H &amp; N Squamous Cell Carcinoma</brief_title>
  <official_title>Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David A. Clump, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-arm phase I/II study establishes the safety and efficacy of low level laser&#xD;
      therapy (LLLT) in order to mitigate radiation-induced dermatitis in patients underoing&#xD;
      radiation therapy for head and neck squamous cell carcinoma (HNSCC). Additional objectives&#xD;
      include assessment of patient-reported quality of life data, pain parameters and dermatologic&#xD;
      quality of life responses. The target population is patients with histologically proven&#xD;
      squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx who are&#xD;
      candidates for either definitive or adjuvant therapy consisting of a chemotherapy regimen and&#xD;
      concurrent radiation therapy.&#xD;
&#xD;
      Patients are required to have a favorable performance status (KPS greater than or equal to&#xD;
      70), have had no prior head and neck radiotherapy and be at least 18 years of age and able to&#xD;
      provide consent. While receiving radiotherapy and a concurrent systemic regimen, patients&#xD;
      will receive LLLT using a 69 diode probe with dual 660 nm and 850 nm wavelengths to at least&#xD;
      nine treatment sites in the head and neck region for a duration of 60 seconds to each site.&#xD;
      LLLT will be given three times in a week prior to, daily during the first week of, and at&#xD;
      least twice weekly thereafter during radiotherapy.&#xD;
&#xD;
      Information collected includes toxicity scoring and quality of life surveys. A retrospective&#xD;
      matched-pair design will be used to assess the rate of grade III complications compared to&#xD;
      patients treated previously without LLLT support, with an anticipated 20% reduction in the&#xD;
      risk of grade III dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the safety and tolerability by documentation of Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low Level Laser Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Level Laser Therapy</intervention_name>
    <description>Red Light Therapy</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients â‰¥ 18 years of age&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70&#xD;
&#xD;
          -  Histologic proof of squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             hypopharynx, or larynx&#xD;
&#xD;
          -  No prior radiotherapy to the head and neck region.&#xD;
&#xD;
          -  No previous systemic chemotherapy or targeted therapy&#xD;
&#xD;
          -  Must be aware of the neoplastic nature of his/her disease and willingly provide&#xD;
             written, informed consent after being informed of the procedure to be followed, the&#xD;
             nature of the therapy, alternatives, potential benefits, side-effects, risks and&#xD;
             discomforts.&#xD;
&#xD;
          -  Patients using standard therapies for cetuximab-induced acne-form rash will be&#xD;
             included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT)&#xD;
             or other staging studies&#xD;
&#xD;
          -  Any co-morbidity or condition of sufficient severity to limit full compliance with the&#xD;
             protocol per assessment by the investigator&#xD;
&#xD;
          -  Concurrent serious infection&#xD;
&#xD;
          -  Continued use of Niacin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Holeva</last_name>
    <phone>412-623-1275</phone>
    <email>holevakd@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Clump</last_name>
    <phone>412-623-6720</phone>
    <email>clumpda2@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Shadyside Radiation Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen D Holeva, BS</last_name>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>David A Clump, MD</last_name>
      <phone>412-623-6720</phone>
      <email>clumpda2@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dwight Heron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Karlovits, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Clump, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Ferris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Ohr, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>David A. Clump, MD, PhD</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

